Kirk's Market Thoughts Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Kirk's Market Thoughts

COHR 129.38

-2.0%

12:11 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

mary-ally-smith

To: Fintas who wrote (2382)	12/18/2014 10:22:11 AM
From: Kirk ©	1 Recommendation of 26408

Nice news today for one of my tiny, biotech newsletter stocks. kirklindstrom.com I had it for the last "Picks of the Quarter" with another bio tech stock for the last contest but unfortunately, did not have it for this contest.... bad timing there! Last two newsletter moves was take profits at $3.60 and buy back at $2.75. I wish they all looked so smart! Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant GlobeNewswire(Thu 7:00AM EST) 7:06 am Agenus announced that its partner GlaxoSmithKline ( GSK) reported that the ZOE-50 Phase 3 study met its primary endpoint ( AGEN) : Analysis of the primary endpoint showed that HZ/su reduced the risk of shingles by 97.2 per cent in adults aged 50 years and older compared to placebo. The study, which started in August 2010, is a randomized, placebo-controlled, multicenter, international study involving 16,136 adults aged 50 and older. An additional GSK trial to evaluate the ability of HZ/su to prevent shingles is underway in adults aged 70 and older.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next